Methylprednisolone

證據等級: L5

預測適應症: 10 個

Methylprednisolone: From Inflammatory/Autoimmune Conditions to Alopecia Areata

One-Sentence Summary

Methylprednisolone is a synthetic glucocorticoid corticosteroid widely used to suppress inflammation and immune responses across a spectrum of autoimmune and inflammatory conditions. The TxGNN model predicts it may be effective for Alopecia Areata, with 1 directly relevant completed clinical trial and 20 publications — many specifically investigating methylprednisolone pulse therapy for this hair loss condition — currently supporting this direction. Evidence level is classified as L2, reflecting a substantive body of prospective cohort and retrospective studies that stop short of a completed Phase 3 RCT.

Quick Overview

Item	Content
Original Indication	Inflammatory and autoimmune conditions (synthetic glucocorticoid corticosteroid)
Predicted New Indication	Alopecia Areata
TxGNN Prediction Score	99.99%
Evidence Level	L2
Canada Market Status	Not Marketed (0 DINs registered in this dataset)
Number of DINs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Alopecia areata (AA) is an autoimmune disease in which CD8+ T cells breach the immune privilege of the hair follicle, triggering an inflammatory cascade that arrests hair growth. Methylprednisolone is a potent synthetic glucocorticoid that acts by binding to the glucocorticoid receptor (GR), which translocates to the nucleus and suppresses NF-κB — a master regulator of pro-inflammatory gene expression. The net result is a marked reduction in T-cell infiltration around the hair follicle and partial restoration of follicular immune privilege.

High-dose “pulse” regimens of methylprednisolone are particularly relevant to this indication. When administered as a bolus (intravenous or oral mega-pulse), the drug achieves peak tissue concentrations sufficient to dampen JAK-STAT and IFN-γ signalling — the same intracellular pathway targeted by newer JAK inhibitors (baricitinib, ritlecitinib) that have received regulatory approval for AA. This mechanistic overlap with validated therapeutic targets provides a strong scientific rationale for the TxGNN prediction.

Corticosteroid pulse therapy for AA is an established, though under-formalised, clinical practice. Multiple prospective open-label studies, retrospective cohorts, and systematic reviews have evaluated both oral and intravenous methylprednisolone specifically in this disease. The primary evidence gap is the absence of a large, blinded Phase 3 RCT; head-to-head data against approved JAK inhibitors are also lacking.

Clinical Trial Evidence

Note: Of 18 clinical trials retrieved, only 1–2 directly investigated methylprednisolone in alopecia areata. The majority studied other agents (JAK inhibitors, biologics) in AA or SLE. High-relevance trials are listed first; lower-relevance trials are included to reflect the research landscape.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01167946	Phase 4	Completed	42	Directly relevant. Oral mega-pulse methylprednisolone in severe, therapy-resistant AA (totalis, universalis, ophiasic subtypes). Used higher doses and more frequent pulses than earlier protocols to overcome known failure modes in severe disease. The sole core trial directly testing this drug-disease pair.
NCT01017510	N/A	Unknown	20	Compared DERMOJET (needle-free device) vs standard syringe for intralesional corticosteroid injection in AA patients. Indirectly supports local steroid delivery in AA; specific corticosteroid agent not specified as methylprednisolone.
NCT07101471	N/A	Completed	296	Observational safety and effectiveness study of tofacitinib (JAK inhibitor) in alopecia; a subset of participants received adjuvant prednisolone, illustrating real-world corticosteroid co-use patterns in this condition.
NCT03252587	Phase 2	Completed	363	BMS-986165 (deucravacitinib) in systemic lupus erythematosus — context trial demonstrating active immunological drug development in immune-mediated alopecia-related conditions.
NCT03843125	Phase 3	Terminated	1,147	Baricitinib long-term safety in SLE; terminated. Represents a JAK inhibitor mechanistically downstream of methylprednisolone’s IFN-γ/JAK-STAT suppression, contextualising the competitive treatment landscape.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
22426909	2012	Prospective Open-Label Trial	Saudi Medical Journal	Oral mega-pulse methylprednisolone for severe therapy-resistant AA. Published results corresponding to NCT01167946; directly evaluates efficacy and safety of the specific drug in this indication.
35986630	2022	Retrospective Cohort	Dermatologic Therapy	Methylprednisolone alone vs methylprednisolone + methotrexate in 26 patients with extensive AA; assessed whether combination therapy offers superior outcomes.
25566921	2015	Prospective Cohort	Indian J Dermatol Venereol Leprol	IV methylprednisolone pulse therapy in severe, extensive, therapy-resistant AA; evaluated as a systemic corticosteroid strategy where conventional therapy has failed.
9777767	1998	Prospective Open-Label	J Am Acad Dermatology	Single IV methylprednisolone pulse in 45 patients with severe AA of <12 months’ duration; one of the earliest systematic evaluations of this regimen.
21592197	2011	Retrospective Cohort	The Journal of Dermatology	Prognostic factors for response to methylprednisolone pulse therapy in 70 AA patients; aimed at establishing proper treatment indications for this regimen.
30745958	2019	Retrospective Study	Open Access Macedonian J Med Sci	Methotrexate + mini-pulse methylprednisolone in severe AA totalis/universalis; Vietnamese cohort experience with combination protocol.
32270396	2020	Systematic Review	Dermatology and Therapy	Cyclosporine with and without systemic corticosteroids in AA; synthesises the role of corticosteroid co-administration in combination protocols.
37992355	2023	Narrative Review	Dermatology Practical & Conceptual	Comprehensive review of corticosteroid pulse therapy in AA: efficacy, relapse rates, side effects, and prognostic factors across different pulse regimens.
18608727	2008	Comparative Study	J Dermatological Treatment	Combination cyclosporine + methylprednisolone for chronic severe AA; addressed the high recurrence rates and toxicity seen with cyclosporine monotherapy alone.
36865845	2022	Retrospective Study	Indian Journal of Dermatology	Sex differences in AA response to steroid pulse therapy; retrospective analysis with literature review, relevant to patient stratification considerations.

Canada Market Information

No DIN records are registered for methylprednisolone in this dataset (market status: not marketed, 0 licences on file).

Important caveat: Methylprednisolone is a long-established drug internationally (marketed as Medrol® tablets and Solu-Medrol® injection). The absence of DIN data in this evidence pack likely reflects a data collection gap rather than actual non-availability in Canada. Verification via Health Canada’s Drug Product Database (https://health-canada.ca/dpd) is strongly recommended before drawing regulatory conclusions.

Safety Considerations

Please refer to the package insert for safety information.

Methylprednisolone is a systemic corticosteroid; standard glucocorticoid safety considerations apply (HPA axis suppression, immunosuppression, metabolic effects, osteoporosis risk with prolonged use). Formal safety data were not retrievable from this evidence pack and must be obtained from the Health Canada product monograph or DrugBank (DB00959) prior to any clinical planning.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: A converging body of evidence — including one completed Phase 4 trial directly testing methylprednisolone in severe therapy-resistant AA, alongside more than a dozen prospective/retrospective cohort studies and systematic reviews in the same indication — provides meaningful clinical support for this TxGNN prediction. The mechanistic rationale is strong (GR-mediated suppression of follicular T-cell infiltration, with functional overlap with the JAK-STAT pathway targeted by approved AA biologics). However, the absence of a Phase 3 blinded RCT, the unresolved Canada regulatory data gap, and the emergence of approved JAK inhibitors as the new standard of care all require a cautious, monitored approach before positioning methylprednisolone as a repurposing candidate for AA in the Canadian market.

To proceed, the following is needed:

Confirm Health Canada DIN status for methylprednisolone products (Medrol®/Solu-Medrol®) via the Drug Product Database — the current “not marketed” flag is suspected to be a data gap
Retrieve full mechanism of action (MOA) data from DrugBank (DB00959) to formalise the pharmacological rationale
Obtain safety warnings, contraindications, and drug interaction data from the Health Canada product monograph
Define the target patient population precisely: evidence is strongest for severe/extensive AA (totalis, universalis, ophiasic subtypes); evidence in mild/patchy AA is less compelling
Assess positioning relative to approved JAK inhibitors (baricitinib FDA-approved 2022, ritlecitinib FDA-approved 2023) — methylprednisolone pulse may serve as a bridge therapy or option in patients who are ineligible for or unable to access JAK inhibitors
Consider a prospective registry or comparative effectiveness study design given the existing evidence base and the ethical difficulty of placebo-controlled trials in a disease with available treatments
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.